QR 060127
Alternative Names: QR-060127Latest Information Update: 19 Sep 2023
At a glance
- Originator Wuhan Createrna Science and Technology
- Class Analgesics; Anti-inflammatories; Antitussives; Urologics
- Mechanism of Action Transient receptor potential channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cough
- Preclinical Focal segmental glomerulosclerosis; Inflammatory pain
Most Recent Events
- 26 May 2023 Center for Drug Evaluation (CDE) of the State Food and Drug Administration approves clinical trial application for QR 060127 in Cough (before May 2023)
- 05 Jul 2022 Phase-I clinical trials in Cough (In volunteers) in China (PO) (ChiCTR2200061875)
- 10 Mar 2022 Preclinical trials in Focal segmental glomerulosclerosis in China (PO) (before March 2022)